Cite
O-5 Efficacy and safety of nivolumab + ipilimumab in Asian patients with advanced hepatocellular carcinoma: Subanalysis of the CheckMate 040 study
MLA
S.P. Choo, et al. “O-5 Efficacy and Safety of Nivolumab + Ipilimumab in Asian Patients with Advanced Hepatocellular Carcinoma: Subanalysis of the CheckMate 040 Study.” Annals of Oncology, vol. 31, July 2020, p. 233. EBSCOhost, https://doi.org/10.1016/j.annonc.2020.04.058.
APA
S.P. Choo, Thomas Yau, Y H Kim, Jaclyn Neely, Yee Chao, Yun Shen, M. Ikeda, H.Y. Lim, Y. Kang, Ming-Mo Hou, Marina Tschaika, Masatoshi Kudo, Tae-You Kim, & C.-H. Hsu. (2020). O-5 Efficacy and safety of nivolumab + ipilimumab in Asian patients with advanced hepatocellular carcinoma: Subanalysis of the CheckMate 040 study. Annals of Oncology, 31, 233. https://doi.org/10.1016/j.annonc.2020.04.058
Chicago
S.P. Choo, Thomas Yau, Y H Kim, Jaclyn Neely, Yee Chao, Yun Shen, M. Ikeda, et al. 2020. “O-5 Efficacy and Safety of Nivolumab + Ipilimumab in Asian Patients with Advanced Hepatocellular Carcinoma: Subanalysis of the CheckMate 040 Study.” Annals of Oncology 31 (July): 233. doi:10.1016/j.annonc.2020.04.058.